ストックスクリーナーアプリを入手
9.40
6.47%
-0.64
前日終値:
$10.04
開ける：
$10.05
24時間の取引高:
182.70K
Relative Volume:
0.22
時価総額：
$498.27M
収益：
-
当期純損益:
$-29.44M
株価収益率:
-10.55
EPS:
-0.8906
ネットキャッシュフロー:
$-24.66M
1週間 パフォーマンス:
-3.69%
1か月 パフォーマンス:
-12.81%
6か月 パフォーマンス:
+247.78%
1年 パフォーマンス:
+498.09%
1日の値動き範囲:
$9.26
$10.05
1週間の範囲:
$9.12
$10.16
52週間の値動き範囲:
$1.60
$11.61
Immix Biopharma Inc Stock (IMMX) Company Profile
名前
Immix Biopharma Inc
セクター
電話
(888) 958-1084
住所
11400 WEST OLYMPIC BLVD., LOS ANGELES
Compare IMMX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
9.3992 | 532.24M | 0 | -29.44M | -24.66M | -0.8906 |
VRTX
Vertex Pharmaceuticals Inc
|
441.17 | 112.35B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.71B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
833.10 | 52.29B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
327.31 | 44.48B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
320.58 | 35.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immix Biopharma Inc Stock (IMMX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-25 | 開始されました | Morgan Stanley | Overweight |
| 2026-03-09 | 開始されました | Citizens | Mkt Outperform |
| 2026-02-09 | 開始されました | Mizuho | Outperform |
Immix Biopharma Inc (IMMX) 最新ニュース
Immix Biopharma (IMMX) price target increased by 11.73% to 18.62 - MSN
Moving Averages: Should I trade or invest in Immix Biopharma IncWall Street Watch & Precise Swing Trade Alerts - baoquankhu1.vn
IMMX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Bear Alert: Is Immix Biopharma Inc in a bullish channel2026 Analyst Calls & Weekly High Conviction Ideas - baoquankhu1.vn
Guidance Update: Is Immix Biopharma Inc stock a buy or sell2026 Bull vs Bear & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Immix rises as Morgan Stanley starts with bullish view on CAR-T therapy - MSN
Immix Biopharma to Participate in Jefferies Global Healthcare Conference - National Today
Immix Biopharma to Host Investor Meetings at Jefferies Global Healthcare Conference 2026 - Quiver Quantitative
Immix Biopharma lines up investor meetings at Jefferies event - Stock Titan
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference - Bitget
Immix Biopharma (IMMX) seeks approval of board slate, auditor and reviews 2025 executive pay - Stock Titan
Earnings Recap: Is Immix Biopharma Inc benefiting from innovation trendsNew Guidance & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Immix Biopharma, Inc. (NASDAQ:IMMX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Immix Biopharma Stock Price Forecast. Should You Buy IMMX? - stockinvest.us
Citizens Initiates Coverage of Immix Biopharma (IMMX) with Market Outperform Recommendation - MSN
IMMX PE Ratio & Valuation, Is IMMX Overvalued - Intellectia AI
Immix Biopharma ― NEXICART-2 の進展で勢いが増す - Smartkarma
Weekly Earnings: Is Immix Biopharma Inc stock a buy or sell2026 Chart Watch & Daily Entry Point Alerts - baoquankhu1.vn
Bear Alert: Is Immix Biopharma Inc benefiting from innovation trends2026 WrapUp & Smart Swing Trading Techniques - baoquankhu1.vn
Citizens reiterates Immix Biopharma stock rating on trial enrollment By Investing.com - Investing.com South Africa
Citizens reiterates Immix Biopharma stock rating on trial enrollment - Investing.com
Immix Biopharma completes enrollment in AL amyloidosis trial By Investing.com - Investing.com South Africa
Immix Biopharma (IMMX) price target increased by 25.64% to 16.66 - MSN
Immix Biopharma Completes NEXICART-2 Enrollment for NXC-201 - tipranks.com
Immix completes enrollment in NEXICART-2; topline results expected Q3 2026 - TradingView
[8-K] Immix Biopharma, Inc. Reports Material Event - stocktitan.net
Immix Biopharma Completes Enrollment for Key AL Amyloidosis Trial - nationaltoday.com
Immix Biopharma (NASDAQ:IMMX) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat
Immix Biopharma Inc Announces Enrollment Completion Of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2 And Upcoming Milestones - marketscreener.com
Immix Biopharma completes enrollment in AL amyloidosis trial - Investing.com
Immix Biopharma, Inc. has announced the successful completion of patient enrollment for its Nexicart-2 trial in relapsed/refractory AL amyloidosis, which supports the Biologics License Application (BLA). - Bitget
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones - The Manila Times
Mizuho raises Immix Biopharma stock price target on cash position By Investing.com - Investing.com India
Mizuho raises Immix Biopharma stock price target on cash position - Investing.com
Should I trade or invest in Immix Biopharma Inc2026 Breakouts & Breakdowns & Proven Capital Preservation Tips - baoquankhu1.vn
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Immix Biopharma, Inc. 2025 Annual Report Amendment: Financial Statements, Auditor Correction, and Company Overview - Minichart
Immix Biopharma (NASDAQ:IMMX) Issues Quarterly Earnings Results - MarketBeat
Immix Biopharma (NASDAQ: IMMX) widens 2025 loss but ends year with $100M cash - stocktitan.net
Mizuho raises Immix Biopharma stock price target to $15 on cash position - Investing.com Australia
Mizuho raises Immix Biopharma stock price target to $15 on cash position By Investing.com - Investing.com South Africa
Citizens Jmp Reaffirms Market Outperform Rating for Immix Biopharma (NASDAQ:IMMX) - MarketBeat
Immix Biopharma Inc (IMMX) 財務データ
収益
当期純利益
現金流量
EPS
Immix Biopharma Inc (IMMX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Morris Gabriel S | CFO |
Dec 10 '25 |
Buy |
6.58 |
770 |
5,067 |
291,429 |
| Rachman Ilya M | CEO and Chairman |
Sep 17 '25 |
Buy |
2.02 |
2,500 |
5,050 |
1,140,937 |
| Morris Gabriel S | CFO |
Sep 16 '25 |
Buy |
1.97 |
2,600 |
5,122 |
290,659 |
| Rachman Ilya M | CEO and Chairman |
Jun 18 '25 |
Buy |
2.29 |
2,178 |
4,999 |
1,138,437 |
| Morris Gabriel S | CFO |
Jun 18 '25 |
Buy |
2.28 |
2,225 |
5,071 |
288,059 |
1.97%
1.62%
大文字化:
|
ボリューム (24 時間):